EGF and prostate carcinoma: To achieve selectively into cancer cells, we engineered a fusion protein epidermal growth factor (EGF)-SubA, combining EGF with SubA, which demonstrated significant inhibition of human breast and prostate cancer cells in vitro and in vivo[16].